SCHEMBL9963140

SCHEMBL9963140

CC(C)N1CCCC(c2nc3ccccc3o2)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.47
LMNA P02545 5/20 0.47
PRKDC P78527 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
THRB P10828 4/20 0.45
USP2 O75604 1/20 0.44
HTR2B P41595 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
TP53 P04637 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361620 0.84 LMNA (0.57) LMNAALDH1A1MAPTMAPK1THRB
SCHEMBL11932553 0.80 PRKDC (0.43) LMNAPRKDCALDH1A1MAPTMAPK1
SCHEMBL14895871 0.77 LMNA (0.57) KCNH2LMNAALDH1A1MAPTTHRB
SCHEMBL4457699 0.77 RAB9A (0.59) KCNH2LMNAALDH1A1MAPTTHRB
SCHEMBL11938949 0.77 POLB (0.50) LMNAPRKDCDRD2DRD3
SCHEMBL17141985 0.76 USP2 (0.47) LMNAALDH1A1MAPTMAPK1THRB
SCHEMBL1128181 0.76 RAB9A (0.62) KCNH2LMNAALDH1A1THRBUSP2
SCHEMBL26862272 0.74 LMNA (0.60) KCNH2LMNAALDH1A1MAPTTHRB
SCHEMBL13810503 0.74 LMNA (0.61) LMNAALDH1A1MAPTMAPK1THRB
SCHEMBL24481595 0.72 LMNA (0.50) LMNAALDH1A1MAPTMAPK1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 KCNH2 409/4885LMNA 1824/4885PRKDC 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.